Npm1 is a haploinsufficient suppressor of myeloid and lymphoid malignancies in the mouse.

Blood
Paolo SportolettiPier Paolo Pandolfi

Abstract

Nucleophosmin (NPM1) gene has been heavily implicated in cancer pathogenesis both as a putative proto-oncogene and tumor suppressor gene. NPM1 is the most frequently mutated gene in acute myeloid leukemia (AML), while deletion of 5q, where NPM1 maps, is frequent in patients with myelodysplastic syndromes (MDS). We have previously shown that mice heterozygous for Npm1 (Npm1+/-) develop a hematologic syndrome with features of human MDS. Here we analyzed Npm1+/- mutants to determine their susceptibility to cancer. Npm1+/- mice displayed a greater propensity to develop malignancies compared with Npm1+/+ mice. The Npm1+/- cohort frequently developed hematologic malignancies of both myeloid and lymphoid origin with myeloid malignancies displaying the highest incidence. Malignant cells retained the wild-type allele with normal localization and expression of Npm1 at the protein level, suggesting that complete Npm1 loss is not a prerequisite for tumorigenesis. Our results conclusively demonstrate that Npm1 acts as a haploinsufficient tumor suppressor in the hematopoietic compartment.

References

Oct 21, 2000·Molecular Pathology : MP·P Mendes-da-SilvaC Monteiro
Jun 19, 2002·Blood·Scott C KoganUNKNOWN Hematopathology subcommittee of the Mouse Models of Human Cancers Consortium
Jan 22, 2005·The New England Journal of Medicine·Brunangelo FaliniUNKNOWN GIMEMA Acute Leukemia Working Party
Jul 12, 2005·Nature·Silvia GrisendiPier Paolo Pandolfi
Jun 24, 2006·Nature Reviews. Cancer·Silvia GrisendiPier Paolo Pandolfi
Dec 13, 2006·Leukemia Research·Harold J Olney, Michelle M Le Beau

❮ Previous
Next ❯

Citations

Jun 3, 2008·Annals of Hematology·Florian Nolte, Wolf-K Hofmann
Oct 16, 2010·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Mar TormoMarisa Calabuig
Aug 13, 2011·Nature·Alice H BergerPier Paolo Pandolfi
Nov 6, 2009·The New England Journal of Medicine·Ayalew Tefferi, James W Vardiman
Sep 23, 2009·Current Opinion in Oncology·Brunangelo FaliniMaria Paola Martelli
Dec 14, 2011·Hematology·Timothy Graubert, Matthew J Walter
Aug 12, 2009·Blood·Olivier KosmiderUNKNOWN Groupe Francophone des Myélodysplasies
Mar 1, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andres JerezJaroslaw P Maciejewski
Mar 13, 2010·Future Oncology·Florian Nolte, Wolf-K Hofmann
Aug 28, 2014·Bioinformatics·Michael P SchroederNuria Lopez-Bigas
Sep 1, 2012·Annual Review of Pathology·R Coleman Lindsley, Benjamin L Ebert
Dec 18, 2013·Oncogene·H K EliasU Steidl
Jul 16, 2014·Expert Review of Hematology·Muneera Al-Hussaini, John F DiPersio
Sep 19, 2009·Expert Review of Anticancer Therapy·Natalia Meani, Myriam Alcalay
Feb 22, 2011·Regulatory Toxicology and Pharmacology : RTP·Jenny L ZhengCarole L Yauk
Apr 3, 2010·Hematology/oncology Clinics of North America·Rafael Bejar, Benjamin L Ebert
Apr 3, 2010·Hematology/oncology Clinics of North America·Sarah H Beachy, Peter D Aplan
Dec 5, 2009·Chemico-biological Interactions·Zhijian QianMichelle M Le Beau
Mar 5, 2009·Journal of Cellular Physiology·Yukiko KomenoToshio Kitamura
Jan 15, 2009·Journal of Internal Medicine·M Jädersten, E Hellström-Lindberg
Dec 3, 2010·The Journal of Pathology·Alice H Berger, Pier Paolo Pandolfi
Apr 16, 2011·British Journal of Haematology·Andrea PellagattiJacqueline Boultwood
Jun 22, 2011·The American Journal of Pathology·Piia-Riitta KarhemoPirjo Laakkonen
Nov 13, 2013·Seminars in Hematology·Olga A Guryanova, Ross L Levine

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.